[Ad hoc announcement pursuant to Art. 53 LR] Roche's Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trialGlobeNewsWire • 01/19/23
Genentech's Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III TrialBusiness Wire • 01/19/23
Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and aboveGlobeNewsWire • 01/12/23
FDA grants priority review to Roche's bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphomaGlobeNewsWire • 01/06/23
FDA Grants Priority Review to Genentech's Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell LymphomaBusiness Wire • 01/06/23
Nimble Therapeutics Announces Expansion of its Discovery and Development Partnership with GenentechBusiness Wire • 01/05/23
FDA approves Roche's Lunsumio, a first-in-class bispecific antibody, to treat people with relapsed or refractory follicular lymphomaGlobeNewsWire • 12/23/22
FDA Approves Genentech's Lunsumio, a First-in-Class Bispecific Antibody, to Treat People With Relapsed or Refractory Follicular LymphomaBusiness Wire • 12/23/22
FDA approves Roche's Actemra for the treatment of COVID-19 in hospitalised adultsGlobeNewsWire • 12/21/22
FDA Approves Genentech's Actemra for the Treatment of COVID-19 in Hospitalized AdultsBusiness Wire • 12/21/22
CHMP recommends expansion of EU label for Hemlibra to include people with moderate haemophilia AGlobeNewsWire • 12/16/22
New Survey Shows Many Americans Are Confused by Testing Options for COVID-19 and FluPRNewsWire • 12/15/22
Roche announces U.S. collaboration with Pfizer to help patients who test positive for COVID-19 navigate risks, symptoms, testing and treatment optionsGlobeNewsWire • 12/14/22